Finerenone Tablets 20 mg is a highly selective, non-steroidal mineralocorticoid receptor antagonist (MRA).
It selectively blocks overactivation of the mineralocorticoid receptor, reducing inflammation, fibrosis, and damage to the kidneys and heart, without the metabolic side effects of traditional steroidal MRAs.
Composition
Each film‑coated tablet contains:
Finerenone …… 20 mg
Indications
For the treatment of chronic kidney disease (CKD) associated with type 2 diabetes mellitus in adults, to reduce the risk of sustained eGFR decline, end‑stage kidney disease, cardiovascular death, non‑fatal myocardial infarction, and hospitalization for heart failure.
Key Features
Highly selective non‑steroidal mineralocorticoid receptor antagonist
Effective renal and cardiovascular protection
Lower risk of hyperkalemia compared with traditional steroidal MRAs
Once‑daily oral administration
Good safety and tolerability profile
Manufactured under strict GMP standards
Complies with USP, EP and other international pharmacopoeial standards
Complete registration dossiers available for global markets
Storage
Store in a cool, dry place, protected from light and moisture.
Keep out of reach of children.
Important Note
Contraindicated in patients with hypersensitivity to finerenone or any excipient.
Contraindicated in patients with adrenal insufficiency.
Monitor serum potassium and renal function during treatment.
For prescription use only, under specialist supervision.
